tetano
Editor, Senior Moderator
Clin Ophthalmol
. 2021 Dec 22;15:4795-4800.
doi: 10.2147/OPTH.S344937. eCollection 2021.
Characteristics and Outcomes of a Series of COVID-Associated Mucormycosis Patients in Two Different Settings in Egypt Through the Third Pandemic Wave
Yousef A Fouad[SUP] 1 2 [/SUP], Hatem M Bakre[SUP] 3 [/SUP], Mahmoud A Nassar[SUP] 4 [/SUP], Mohamed Omar A Gad[SUP] 5 [/SUP], Ashraf Abdelsalam Kandeel Shaat[SUP] 1 2 [/SUP]
Affiliations
Abstract
Purpose: To report on the underlying risk factors, clinical characteristics, presentation, and survival of coronavirus disease 2019 (COVID-19) associated mucormycosis (CAM) cases referred for ophthalmological consultation in two different Egyptian settings during the third viral pandemic wave (April to August of 2021).
Methods: A multicentric, retrospective analysis involving one public and two private hospitals in metropolitan Cairo, and two university hospitals in upper Egypt (Aswan and Assuit). Cases that fulfilled the diagnostic criteria of mucormycosis, with a prior or concurrent COVID-19 infection, were included.
Results: Of the 26 patients included in the final analysis, 15 (57.7%) were from Cairo and 11 (42.3%) were from upper Egypt. Twenty-five patients (96.2%) had poorly controlled diabetes mellitus and 20 (76.9%) had received corticosteroid treatment for COVID-19, of which 30.8% had mild or moderate disease. The median duration from COVID-19 till the onset of CAM was 20.5 days. No visual function could be detected in the affected eye of 16 patients (61.6%) on presentation. The mortality rate was 46.2% despite surgical debridement in half of the cases that died.
Conclusion: CAM continues to be a concrete threat throughout Egypt, especially in patients with poorly controlled diabetes mellitus and those who inadvertently receive steroid therapy. It remains to be seen if increased vaccination coverage and early detection due to increased awareness would result in declining rates and adverse sequelae of CAM. A national registry would allow for better monitoring of the disease trends.
Keywords: COVID-19; COVID-associated mucormycosis; coronavirus disease 2019; invasive fungal sinusitis; mucormycosis.
. 2021 Dec 22;15:4795-4800.
doi: 10.2147/OPTH.S344937. eCollection 2021.
Characteristics and Outcomes of a Series of COVID-Associated Mucormycosis Patients in Two Different Settings in Egypt Through the Third Pandemic Wave
Yousef A Fouad[SUP] 1 2 [/SUP], Hatem M Bakre[SUP] 3 [/SUP], Mahmoud A Nassar[SUP] 4 [/SUP], Mohamed Omar A Gad[SUP] 5 [/SUP], Ashraf Abdelsalam Kandeel Shaat[SUP] 1 2 [/SUP]
Affiliations
- PMID: 34992339
- PMCID: PMC8711239
- DOI: 10.2147/OPTH.S344937
Abstract
Purpose: To report on the underlying risk factors, clinical characteristics, presentation, and survival of coronavirus disease 2019 (COVID-19) associated mucormycosis (CAM) cases referred for ophthalmological consultation in two different Egyptian settings during the third viral pandemic wave (April to August of 2021).
Methods: A multicentric, retrospective analysis involving one public and two private hospitals in metropolitan Cairo, and two university hospitals in upper Egypt (Aswan and Assuit). Cases that fulfilled the diagnostic criteria of mucormycosis, with a prior or concurrent COVID-19 infection, were included.
Results: Of the 26 patients included in the final analysis, 15 (57.7%) were from Cairo and 11 (42.3%) were from upper Egypt. Twenty-five patients (96.2%) had poorly controlled diabetes mellitus and 20 (76.9%) had received corticosteroid treatment for COVID-19, of which 30.8% had mild or moderate disease. The median duration from COVID-19 till the onset of CAM was 20.5 days. No visual function could be detected in the affected eye of 16 patients (61.6%) on presentation. The mortality rate was 46.2% despite surgical debridement in half of the cases that died.
Conclusion: CAM continues to be a concrete threat throughout Egypt, especially in patients with poorly controlled diabetes mellitus and those who inadvertently receive steroid therapy. It remains to be seen if increased vaccination coverage and early detection due to increased awareness would result in declining rates and adverse sequelae of CAM. A national registry would allow for better monitoring of the disease trends.
Keywords: COVID-19; COVID-associated mucormycosis; coronavirus disease 2019; invasive fungal sinusitis; mucormycosis.